CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies

Experimental Hematology

Volumn 33, Issue 3, 2005, Pages 279-285

  Cao, Thai M ^a,d   Wong, Ruby M ^b   Sheehan, Kevin ^c   Laport, Ginna G ^a   Stockerl Goldstein, Keith E ^a   Johnston, Laura J ^a   Shizuru, Judith A ^a   Negrin, Robert S ^a   Lowsky, Robert ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANALYTIC METHOD; ARTICLE; BLOOD; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DONOR; EVALUATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH CENTER; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HLA SYSTEM; HUMAN; INCIDENCE; INFUSION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; THROMBOCYTE; TIME;

EID: 13844320989     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.12.004     Document Type: Article

References (35)

1. S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy J Clin Oncol 18 2000 1360 1377
2. S. Heimfeld HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 31 2003 839 845
3. D. Przepiorka, P. Anderlini, and R. Saliba Chronic graft-versus-host disease after allogeneic blood stem cell transplantation Blood 98 2001 1695 1700
4. S. Yamasaki, H. Henzan, and Y. Ohno Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors Bone Marrow Transplant 32 2003 505 510
5. J.J. Cornelissen, B. van der Holt, and E.J. Petersen A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies Exp Hematol 31 2003 855 864
6. R. Handgretinger, P. Lang, T. Klingebiel, and D. Niethammer CD34 stem cell dose and development of extensive chronic graft-versus-host disease Blood 99 2002 3875 3876
7. S. Singhal, R. Powles, and J. Treleaven A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26 2000 489 496
8. T.M. Cao, C. Kusnierz-Glaz, and F. Valone Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies Cancer 91 2001 2205 2213
9. N.J. Chao, D.S. Snyder, and M. Jain Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial Biol Blood Marrow Transplant 6 2000 254 261
10. N.J. Chao, G.M. Schmidt, and J.C. Niland Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease N Engl J Med 329 1993 1225 1230
11. D.R. Sutherland, L. Anderson, M. Keeney, R. Nayar, and I. Chin-Yee The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering J Hematother 5 1996 213 226
12. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV) Centers for Disease Control and Prevention MMWR Recomm Rep 46 1997 1 29
13. K.M. Sullivan Graft-versus-host disease K.G. Blume S.J. Forman F.R. Appelbaum Thomas' Hematopoietic Cell Transplantation 3rd ed. 2004 Blackwell Science Boston, MA 635 664
14. D.R. Cox Regression models and life tables J R Stat Soc 34 1972 187 220
15. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
16. M. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163
17. M. Mohty, K. Bilger, and E. Jourdan Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation Leukemia 17 2003 869 875
18. O. Ringden, A.J. Barrett, and M.J. Zhang Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses Br J Haematol 121 2003 874 885
19. J.M. Zaucha, T. Gooley, and W.I. Bensinger CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation Blood 98 2001 3221 3227
20. D. Mavroudis, E. Read, and M. Cottler-Fox CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies Blood 88 1996 3223 3229
21. J.E. Wagner, J.N. Barker, and T.E. DeFor Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood 100 2002 1611 1618
22. O. Ringden, M. Remberger, and V. Runde Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation Blood 94 1999 455 464
23. M. Remberger, O. Ringden, and I.W. Blau No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors Blood 98 2001 1739 1745
24. M. Korbling, Y.O. Huh, and A. Durett Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease Blood 86 1995 2842 2848
25. G. Miflin, N.H. Russell, and R.M. Hutchinson Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk Bone Marrow Transplant 19 1997 9 13
26. O. Ilhan, O. Arslan, and M. Arat The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation Transfus Sci 20 1999 69 71
27. N.A. Kernan, N.H. Collins, L. Juliano, T. Cartagena, B. Dupont, and R.J. O'Reilly Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease Blood 68 1986 770 773
28. K. Atkinson, H. Farrelly, M. Cooley, E. O'Flaherty, K. Downs, and J. Biggs Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease Bone Marrow Transplant 2 1987 51 57
29. A. Urbano-Ispizua, C. Rozman, and P. Pimentel Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings Blood 100 2002 724 727
30. S.K. Sohn, J.G. Kim, D.H. Kim, N.Y. Lee, J.S. Suh, and K.B. Lee Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation Bone Marrow Transplant 31 2003 967 972
31. P.G. Beatty, R.A. Clift, and E.M. Mickelson Marrow transplantation from related donors other than HLA-identical siblings N Engl J Med 313 1985 765 771
32. N.A. Kernan, G. Bartsch, and R.C. Ash Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program N Engl J Med 328 1993 593 602
33. N. Flomenberg, L.A. Baxter-Lowe, and D. Confer Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome Blood 104 2004 1923 1930
34. K.M. Sullivan, E. Agura, and C. Anasetti Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 28 1991 250 259
35. B.L. Stewart, B. Storer, and J. Storek Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood 104 2004 3501 3506